Proteocyte Announces Mark Rood as Key Accounts Director, U.S.

Toronto, ON; June 7, 2024 – Proteocyte is pleased to announce the appointment of Mark Rood as their Director of Key Accounts, USA.

Mr. Rood brings over 15 years of experience in the U.S. surgical device industry including the dental surgery market with companies like Henry Schein, NuVasive, and most recently, Axogen Inc., successfully contributing to high growth and adoption of their allograft nerve in the U.S. market. He has a proven track record of success in market development, executing commercialization plans as well as facilitating clinical education programs for surgeons across the U.S.

Proteocyte’s CEO, Mark Hammar said of the announcement, “The addition of Mark Rood to our U.S. team is a critical next step in our commercialization plan for the U.S. market. Mark brings a tremendous amount of experience in the Oral Health space along with several well-established positive relationships with Key Oral Surgeons across the U.S.”

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.